Trial Profile
Phase I Trial of DNX-2440 Oncolytic Adenovirus in Patients With Recurrent Glioblastoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs DNX 2440 (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions; First in man
- 05 Apr 2023 Status changed from recruiting to discontinued due to break of stock.
- 11 Jun 2020 Status changed from active, no longer recruiting to recruiting.
- 19 Dec 2019 Status changed from recruiting to active, no longer recruiting.